Mistra (Dienogest, Ethinylestradiol)

Dienogest and Ethinylestradiol, the active ingredients in Mistra, are a combined oral contraceptive presented as a tablet for oral use. They work by inhibiting ovulation and altering cervical mucus, providing reliable pregnancy prevention for women of reproductive age. It is indicated for women seeking a reversible, hormone‑based method of contraception and is marketed throughout the European Union.

GNH USA supplies Mistra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mistra, a combined oral contraceptive, is used within the hormonal contraception pathway to prevent pregnancy. - Prevention of pregnancy: provides reliable contraception for women of reproductive age. - Family planning: enables controlled timing of pregnancies. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns.

Mistra may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Irregular bleeding or spotting: changes in menstrual flow. - Weight gain: modest increase in body weight. - Mood changes: fluctuations in emotional state.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: clot migration to the lungs. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events. - Severe hypertension: sudden, high blood pressure. - Hepatic adenoma: benign liver tumor. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

Before prescribing Mistra, clinicians should evaluate individual risk factors and contraindications. - Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used. - History of thromboembolic disorders: increased risk of clotting events; avoid use. - Hypertension screening: monitor blood pressure regularly during therapy. - Liver disease assessment: hepatic impairment may alter hormone metabolism. - Smoking in women over 35: contraindicated due to elevated cardiovascular risk. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Mistra can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (carbamazepine, phenytoin, phenobarbital): may reduce contraceptive effectiveness. - Rifampin or other strong CYP3A4 inducers: may decrease hormone levels and increase risk of unintended pregnancy. - St. John’s wort: may lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, itraconazole): may increase hormone levels; monitor for side effects. - Macrolide antibiotics (erythromycin, clarithromycin): may slightly raise plasma concentrations; observe for increased adverse reactions.